Abstract
Radiation therapy has been used in the adjuvant setting or as a primary treatment modality for esophageal cancer. Although there are design flaws in all of the trials of adjuvant radiation therapy for esophageal cancer, there is no clear survival advantage when radiation therapy is delivered in the adjuvant setting (preoperatively or postoperatively). Phase II results of preoperative, combined modality therapy are encouraging; however, the approach remains investigational. When radiation therapy is used as a primary modality, the most favorable results are seen when it is combined with adequate doses of systemic chemotherapy. Phase III intergroup trials are in progress which are examining the effectiveness of higher doses of radiation therapy when combined with chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 217-235 |
| Number of pages | 19 |
| Journal | Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer |
| Volume | 142 |
| DOIs | |
| State | Published - 1996 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Radiation therapy alone or combined with chemotherapy in the treatment of esophageal cancer.'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS